Mr. Thomas Braun reports

VERISANTE TECHNOLOGY, INC. ANNOUNCES COMPLETION OF PROTOTYPE OF MULTISPECTRAL IMAGING SYSTEM FOR SKIN CANCER

Verisante Technology Inc. has completed the second phase prototype of a rapid multispectral imaging (MSI) system for skin cancer detection.

The MSI device is intended to assist medical professionals in the detection of all major forms of skin cancer. The device takes images of suspicious lesions with more than a dozen different wavelengths of light to capture real-time spectral images in a fraction of a second. These spectral images contain unique information about suspected skin lesions such as tissue oxygenation ratios, hemoglobin levels, melanin levels, scatter sizes and other parameters. The prototype system is currently undergoing laboratory testing at the B.C. Cancer Agency Research Centre prior to starting in vivo data collection for training the predictive algorithm for the device.

"Being able to extract the parameters collected by this MSI system could provide a strong predictive measurement for all major forms of skin cancer," said Dr. Haishan Zeng, a distinguished scientist in the integrative oncology department at the B.C. Cancer Agency.

Verisante licensed the MSI technology from the inventors, Dr. Haishan Zeng and Dr. Yasser Fawzy of the B.C. Cancer Agency, for skin cancer and oral cancer detection as part of a broader acquisition strategy to enhance the company's intellectual property portfolio of different technologies that, in addition to MSI, include white light reflectance imaging, fluorescence imaging and rapid Raman spectroscopy. The MSI camera is intended to be a low-cost, hand-held, portable device that connects to a laptop computer via USB cable to assist in the detection of skin cancer and will be a great addition to the company's existing product line. The company will also explore the possibility of combining the MSI camera with the existing Aura device to determine if the two different technologies produce higher accuracy when results are combined since they are measuring different parameters.

Verisante has filed for patent protection in over 10 jurisdictions on the MSI technology, and the PCT application is now in the final, national and regional phase.

"This is a major milestone for the MSI camera project which began two years ago when it was just an idea on paper. It is finally beginning to look more like a product than a prototype. While it is already lightweight and compact, we anticipate the final version will be even smaller and lighter. This company has demonstrated once again its ability to take projects from the idea stage and create products," said Thomas Braun, chief executive officer. "Once the skin cancer version is proven we will build another version for oral cancer detection."

We seek Safe Harbor.